PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator

PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator

PharmStars, the pharma-focused accelerator for digital health startups, announces it is now accepting applications for its Fall 2022 cohort with the theme, “Innovations in Real-World Evidence.” - June 15, 2022 - PharmStars

Defined Bioscience Announces Formation of Scientific Advisory Board

Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the... - June 15, 2022 - Defined Bioscience Inc.

PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort

PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort

PharmStars, the pharma-focused accelerator for digital health startups, announces the start of its Showcase Event on June 8, 2022. The digital health startups that participated in the 10-week accelerator program will make formal presentations to, and answer questions from, the pharma members of PharmStars. All of PharmStars’ seven members are participating in the Showcase Event. - June 08, 2022 - PharmStars

Molekule Consulting Announces the Launch of E.U. - Based Operations

Molekule Consulting Announces the Launch of E.U. - Based Operations

Molekule Consulting announces the launch of an E.U. - based business / Molekule Hub continuing their focus on the development of global strategy and advisory services for the biopharmaceutical sector. - May 24, 2022 - Molekule Consulting

LifeBiotic's Botanical Formula Shows Significant Destruction of Multiple GI Cancer Cells

In a new cell model study, the patented LCS101 formula eliminated up to 90% of cancer cells within 72 hours. - May 19, 2022 - Lifebiotic

Microvascular Therapeutics Finalizes Facility Certification for the Production of Its Product, MVT-100

Microvascular Therapeutics (MVT), a clinical stage biotechnology company, finalized its manufacturing facility certifications for the GMP production of its first product, MVT-100. - April 21, 2022 - Microvascular Therapeutics

Microvascular Therapeutics Receives Funds from Commercialization Readiness Program for the Development of Its Ultrasound Contrast Agent, MVT-100

MicrovMicrovascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Commercialization Readiness Program grant from the National Institute of Heart, Lung, and Blood Institute (NHLBI). Wyatt Unger, MD, MBA, Chief Medical Officer of MVT said, “We are... - April 09, 2022 - Microvascular Therapeutics

Timothy Healey Joins the Board of Director at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022 - Microvascular Therapeutics

ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit

ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022 - Microvascular Therapeutics

Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022 - Microvascular Therapeutics

Decarbitation Inc. Product Launch: New Cannabis Crude Oil Decarboxylation Technology Using Controlled Cavitation

Decarbitation Inc. Product Launch: New Cannabis Crude Oil Decarboxylation Technology Using Controlled Cavitation

DecarbitationTM will be launching its website as well brand new 2 and 25 gallon systems for the decarboxylation of cannabis on February 2, 2022. - February 01, 2022 - Decarbitation Inc.

PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply

PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply

PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its spring 2022 cohort with the theme, “Digital Innovations in Neurological Disease.” - January 04, 2022 - PharmStars

Mirror Biologics Announces Appointment of Dr. David Fineberg as Chief Medical Officer

Mirror Biologics Announces Appointment of Dr. David Fineberg as Chief Medical Officer

Mirror Biologics, Inc., a clinical stage immunotherapy company specializing in the development, manufacturing, commercialization and clinical translation of next generation immunomodulatory and therapeutic in-situ vaccines for cancer and infectious diseases, today announced the appointment of David... - December 26, 2021 - Mirror Biologics, Inc.

Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round

Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round

This Funding will be Used, in Part, to Launch an Asian Phase II/III Randomized Controlled Registration Trial for Advanced Liver Cancer in Q1/2-2022. - December 09, 2021 - Mirror Biologics, Inc.

PharmStars Announces 2021 Accelerator Graduates

PharmStars Announces 2021 Accelerator Graduates

12 digital health startups have successfully completed PharmStars’ inaugural 10-week pharma-focused accelerator program. - December 08, 2021 - PharmStars

Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201

Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function,... - November 29, 2021 - Parvus Therapeutics U.S., Inc.

Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles

Today Parvus announced it has entered into an agreement with Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO), for process development, scale-up and GMP manufacturing of NavacimTM nanoparticles, a key building block for all of our Navacim platform drug development candidates. - November 19, 2021 - Parvus Therapeutics U.S., Inc.

PharmStars Announces Showcase Event for Inaugural Class

PharmStars Announces Showcase Event for Inaugural Class

PharmStars, a pharma-focused accelerator for digital health startups, announces the start of its 2021 Showcase Event. At the Showcase Event, the 12 startups in the accelerator’s current cohort will pitch their digital health solutions to PharmStars’ pharma members. The startups and pharma members will also have the opportunity to meet privately to discuss potential partnership opportunities. - November 17, 2021 - PharmStars

Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease

Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease

Mirror Biologics, Inc., a private clinical stage biopharmaceutical company, today announces the issuance of US Patent No. 11,160,852, “Method of Vaccinating Using Allogeneic Cells,” covering methods for creating a next generation of therapeutic vaccines against cancers and infectious... - November 17, 2021 - Mirror Biologics, Inc.

PharmStars Welcomes Sumitovant Biopharma as Its Newest Member

PharmStars Welcomes Sumitovant Biopharma as Its Newest Member

PharmStars, the only pharma-focused, member-based accelerator for digital health startups, is pleased to announce that Sumitovant Biopharma has become its newest pharma member, joining existing members including Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk. PharmStars focuses on bridging the "pharma-startup gap." PharmStars provides startups with education and mentoring to help them engage with pharma as clients and partners. - November 03, 2021 - PharmStars

Omni-HC Selected to Participate in “Audience Amplification” Workshop at Prestigious Global Medical Affairs Meeting

Omni Healthcare Communications has been selected by the Medical Affairs Professional Society to convene a workshop on scientific communication amplification at the MAPS 2022 Global Annual Meeting. - October 02, 2021 - Sunny Ayr Holdings

Cayman Chemical Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration

The National Institute of Dental and Craniofacial Research has awarded Cayman Chemical with a $1,700,500 grant to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage... - September 19, 2021 - Cayman Chemical Company

AdvantaPure(R) Announces Fall Trade Show Appearances - Includes Events in the Northeast U.S.

AdvantaPure, the high purity division of NewAge Industries, will exhibit its silicone and TPE tubing and molded assemblies at the ISPE Boston Show, BioProcess International 2021, and Interphex, all taking place in September and October. AdvantaPure will also highlight its recent clean room expansion and its in-process building renovation at the events. The company is increasing its tubing manufacturing capacity to help meet demand for its Single-Use products. - September 16, 2021 - AdvantaPure

Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer

Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer

Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccine immunotherapy for cancer and infectious diseases where... - September 10, 2021 - Mirror Biologics, Inc.

Defined Bioscience Licenses FGF2-STAB (G3) for Use in Stem Cell Media

Defined recently concluded a licensing agreement with Czech Republic-based Enantis for global use of Enantis’ patented FGF2-STAB® technology both alone and in stem cell media formulations. FGF2-STAB®, originally coined FGF2-G3, was developed by Enantis and Masaryk University, using... - August 30, 2021 - Defined Bioscience Inc.

Omni Healthcare Communications & Res Consortium Form Alliance to Expand Medical Affairs Capabilities

Omni Healthcare Communications (Omni-HC), a US based medical communications firm delivering solutions for today’s scientific exchange challenges, is pleased to announce the formation of a strategic alliance with Res Consortium (Res) of the United Kingdom, a cross-sector leader in digital... - August 21, 2021 - Sunny Ayr Holdings

Mirror Biologics Announces Appointment of Global CRO Parexel to Provide Regulatory & Access Consulting Services

Mirror Biologics Announces Appointment of Global CRO Parexel to Provide Regulatory & Access Consulting Services

Mirror Biologics, Inc, (“Mirror” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases, where the active ingredients... - August 02, 2021 - Mirror Biologics, Inc.

ConSep II™ Filter Module, a Game Changer in Fermentation and High Temperature Cross Flow Filtration Applications

ConSep II™ Filter Module, a Game Changer in Fermentation and High Temperature Cross Flow Filtration Applications

The combination of the patented open channel design and the high temperature capabilities of the ConSep II™ filter module provide unique performance characteristics which customers describe as an "enabling technology" and "a game changer." - July 29, 2021 - SmartFlow Technologies

Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)

Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon... - July 19, 2021 - Microvascular Therapeutics

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old

Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases where the active... - July 14, 2021 - Mirror Biologics, Inc.

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer

Mirror Biologics, Inc. (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ cancer vaccines in which the active ingredients are living... - July 09, 2021 - Mirror Biologics, Inc.

Parvus Therapeutics Announces CEO, Senior Executive, and Board of Directors Appointments

Appoints CEO, Senior Executive, and Board of Directors: Peter M. Strumph, Chief Executive Officer; Brendan Classon PhD, Executive Vice President, Research and Development; Louis Demers, Vice President of Technical Operations; Matthew J. Hogan, member of the Board of Directors - July 06, 2021 - Parvus Therapeutics U.S., Inc.

Defined Bioscience Launches with $1.5M SBIR from the NIH to Advance Stem Cell Media

Defined recently received a $1.5M in Phase II SBIR award from the National Institutes of Health to develop defined media over the next two years. - July 03, 2021 - Defined Bioscience Inc.

Updated Findings of COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report

2021 Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing and Changes Since 2020 - May 25, 2021 - Life Science Strategy Group, LLC

eCTD Solutions Appoints New CEO and Changes Name to Highlight Expanded Capability

Sunny Ayr Holdings, a group of healthcare product solutions companies, is pleased to announce the change of the name of eCTD Solutions Ltd. to Omni Early Development Services and the appointment of Mark Marino, MD as Partner and Chief Executive Officer of the early product development solutions provider. - May 19, 2021 - Sunny Ayr Holdings

Advanced Silicon Group Closes Seed Preferred Equity Offering and Adds Alan Watson and Sarah Kelly to Board

Advanced Silicon Group, Inc. (ASG), a pioneer in silicon nanotechnology focused on developing novel biosensors, announced today the closing of a $1,020,000 seed preferred stock offering led by Cherrystone Angel Group with participation by MIT Alumni Angels of Northern California, Sidecar Angels and other private investors and the addition of two new Directors, Alan Watson, PhD, MBA and Sarah Kelly, PhD to its Board of Directors. - May 16, 2021 - Advanced Silicon Group

Cayman Develops Powerful, New Multiplex ELISA for Autoantibody Detection

Cayman Chemical's new Q-Plex™ Autoantibody Detection 10-Plex Panel, developed in collaboration with Quansys Biosciences, offers standardized, multiplex capabilities for the concurrent analysis of ten prominent analytes associated with rheumatoid arthritis or other autoimmune diseases. This... - May 16, 2021 - Cayman Chemical Company

Mirror Biologics, Inc. Announces Appointment of Interim CEO

Mirror Biologics, Inc. Announces Appointment of Interim CEO

Mirror Biologics, Inc., a clinical stage biopharmaceutical company developing next generation immunotherapy treatments for cancer and infectious diseases, announces the appointment of Adi Raviv as interim Chief Executive Officer and member of the Board of Directors. "Adi brings a depth of... - May 12, 2021 - Mirror Biologics, Inc.

Cayman Adds Nordic BioSite as Trusted Distributor

Cayman Chemical’s complete assay kit, protein, antibody, and biochemical portfolio is now more accessible to Denmark, Finland, Iceland, Norway, Sweden, and the Baltic countries as well as Russia through a distribution agreement with Nordic BioSite. Headquartered in Täby, Sweden, Nordic... - February 10, 2021 - Cayman Chemical Company

AltuCell Therapeutics Announces Proof-of-Concept in Lead Programs in Type 1 Diabetes in Human Subjects; Phase 1 Pilot in Humans Has IND Approval & Trial to Begin Shortly

AltuCell Therapeutics, Inc., AltuCell announced today the achievement of approval of IND in Italy after pre-clinical proof-of-concept based on data from its two lead programs for type 1 diabetes testing of cadaver stem cell-derived islets in both human and non-human subjects. Their capsules have been implanted in people with diabetes for 5 year, demonstrating long-term safety, with no toxicity or tissue necrosis, and no rejection in any of the patients treated. - January 15, 2021 - AltuCell Therapeutics

Cayman Breaks Ground on State-of-the-Art Facility Projecting Future Growth in R&D

Cayman held a groundbreaking ceremony to start the buildout of a $20 million research and development facility at its headquarters in Ann Arbor, MI. - November 07, 2020 - Cayman Chemical Company

3Sixty Pharma Solutions Announces Successful Approval of FDA Investigational New Drug Application

3Sixty Pharma Solutions LLC., www.3sixtypharma.com, has announced the successful submission to FDA, and approval of, an Investigational New Drug (IND) Application on behalf of one of its clinical-stage biotech clients. 3Sixty Pharma Solutions’ 360 Start-Up arm continues to be committed to... - October 15, 2020 - 3Sixty Pharma Solutions

Cayman Receives SBIR Grant for Alzheimer’s Research

The National Institute on Aging (NIA) has awarded Cayman Chemical with a Phase II Small Business Innovation Research (SBIR) grant to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies. - October 10, 2020 - Cayman Chemical Company

New eClinical Platform Strategic Analysis & Competitive Landscape Report

Survey Quantifies eClinical Platform Use and Satisfaction and Identifies Dramatic Perceptual Changes - August 26, 2020 - Life Science Strategy Group, LLC

Grants Available for Undergraduate Students Seeking Research Experience

Cayman Biomedical Research Institute (CABRI) is now accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted until September 20, 2020, for awards to be distributed by November 2, 2020. Grants range from $2,000 - $5,000 and may be awarded as individual or group grants. - August 19, 2020 - Cayman Chemical Company

Cayman and GenScript Partner to Offer Neoantigen Profiling and Synthesis Expertise

Cayman and GenScript have come together to create a complete package of neoantigen discovery services. Through combined efforts, MHC-associated peptides are identified and verified as immunogenic to guide peptide synthesis for vaccine development. “Cayman provides a complete workflow enabling... - August 15, 2020 - Cayman Chemical Company

Microvascular Therapeutics Receives NIH SBIR Phase I Funds for Its Alzheimer Program

Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Institute of Aging (NIA), part of the National Institutes of Health (NIH). Wyatt Unger, MD, MBA, President and CEO of MVT said,... - August 03, 2020 - Microvascular Therapeutics

Microvascular Therapeutics Receives NIH SBIR Phase I Funds for Its Program to Treat Heart Attack

Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health. Wyatt Unger, MD, MBA, President and CEO of... - July 31, 2020 - Microvascular Therapeutics

Part B Access for Seniors and Physicians (ASP) Coalition Statement Regarding the Trump Administration’s Recently Announced Executive Order

The Part B Access for Seniors and Physicians (ASP) Coalition released the following statement regarding the Trump Administration’s recently announced Executive Order: “In a letter to lawmakers in 2018, the ASP Coalition warned about the International Pricing Index Model (IPI) and the... - July 24, 2020 - Part B Access for Seniors and Physicians Coalition

EUPROTEIN Launched the Supreme Humanly-Expressed Proteins to Help Research in SARS-CoV-2

EUPROTEIN Inc., the expert in mammalian expressed protein, has launched the full set of their top-quality recombinant proteins to help researchers around the world for their studies towards this global pandemic. These protein are expressed in human mammalian cells, which inherently is of superior quality compared to those expressed from E. Coli. - July 09, 2020 - EUPROTEIN Inc.

Press Releases 1 - 50 of 674